Identifying immune escape mechanisms used by tumors may define strategies to sensitize them to immunotherapies to which they are otherwise resistant. In this study, we show that the antiapoptotic gene API5 acts as an immune escape gene in tumors by rendering them resistant to apoptosis triggered by tumor antigen-specific T cells. Its RNAi-mediated silencing in tumor cells expressing high levels of API5 restored antigen-specific immune sensitivity. Conversely, introducing API5 into API5 low cells conferred immune resistance. Mechanistic investigations revealed that API5 mediated resistance by upregulating FGF2 signaling through a FGFR1/PKCd/ERK effector pathway that triggered degradation of the proapoptotic molecule BIM. Blockade of FGF2, PKCd, or ERK phenocopied the effect of API5 silencing in tumor cells expressing high levels of API5 to either murine or human antigen-specific T cells. Our results identify a novel mechanism of immune escape that can be inhibited to potentiate the efficacy of targeted active immunotherapies. Cancer Res; 74(13); 3556-66. Ó2014 AACR.
Introduction
Despite the presence of a competent immune system, tumor cells may elude detection from host immune surveillance through a process of cancer immune editing. In this process, elimination of tumor cells sensitive to host immune attack leads to the selection and survival of immune-resistant cancer cells. For this reason, immune-based strategies can engender an initial response, but recurrences are common as immuneresistant tumor cell variants develop under immunoselective pressure. Extrinsic mechanisms associated with upregulation of immunosuppressive cytokines such as TGFb and IL10 and the accumulation of regulatory cells (1) (2) (3) (4) can exacerbate the immune inhibitory milieu, whereas intrinsic genetic instability can generate cells resistant to immune eradication (5) . Therefore, successful anticancer therapies depend on the control of tumor cell growth and their microenvironment along with strategies to overcome immune tolerance in patients. However, the current understanding of molecular mechanisms and signaling pathways underlying tumor immune evasion remains nascent and calls for the identification of master factors governing immune escape.
In an effort to elucidate potential targetable pathways of immune resistance and restore immune sensitivity, we dissected the immune resistance phenotype with the prospect of identifying a master gene regulating tumor immune escape. Our studies in the murine model utilized a highly immuneresistant cervical tumor cell subline, TC-1/P3/A17, generated by serial in vivo selection of its immune-susceptible parental cell line TC-1/P0 expressing the CTL target antigen, HPV16/E7 (6) . This model allowed us to use E7-specific CTL to assess immune sensitivity both in vitro and in vivo tumor models. Comparative microarray analysis revealed selective overexpression of an antiapoptotic gene, apoptosis inhibitor 5 (API5), in the immune-resistant phenotype. Through a series of in vitro and in vivo assays assessing immune sensitivity, we found that API5 plays a critical role as a master regulator of tumor immune escape in mouse. We also validate the role of API5 as an immune escape factor in human cancer cells by using a CTL clone generated from patients with melanoma that recognizes an endogenous tumor-associated antigen, MART-1. Furthermore, we define a new pathway involved in API5-induced immune resistance that is dependent on the secretion of FGF2 and downstream FGFR1 receptor signaling, which triggers specific degradation of the proapoptotic molecule, BIM, by PKCd-dependent ERK activation. Therefore, our data uncover a major axis of tumor immune resistance regulated by API5 and underline the necessity for combinatorial strategies that include targeting API5 to circumvent tumor immune resistance in patients with cancer.
Materials and Methods

Chemical kinase inhibitors
LY294002 (Calbiochem Corp) for PI3K, API-2 (Calbiochem Corp) for AKT, SB203580 (Calbiochem Corp.) for p38, PD98059 (Stressgen) for ERK, and rottlerin for PKCd (Sigma) were used to specifically suppress the activity of indicated kinases.
Flow-cytometric analysis and CTL assays
For in vitro CTL assays, 1 Â 10 5 E7-expressing or MART-1-expressing/HLA-A2-restricted M27 peptide pulsed tumor target cells were incubated with murine E7-specific CD8 þ T cells or MART-1-specific human CD8
þ T cells, respectively, at 1:1 ratio for 4 hours. The percentages of active caspase-3 þ tumor cells were measured by flow cytometry to determine the level of apoptotic cell death. All analysis was performed using a Becton Dickinson FACScan with CELLQuest software (BD Biosciences).
Inhibition of BIM degradation
To measure the stability of BIM, MG132 (Calbiochem) was dissolved in DMSO and then added to a final concentration of 25 mmol/L for 3 hours to inhibit proteasome activity.
Real-time quantitative RT-PCR
The total RNAs of the cells were isolated using TRIzol reagent (Invitrogen). First-strand synthesis were performed by using RT&Go Mastermix (MP Biomedicals) and real-time PCR was performed by a Lightcycler Fast start DNA SYBR Green Master Mix (Roche) using specific primers with the following sequences (rates normalized to the expression level of actin): hAPI5, 5;-GGGCAAAAGAGAGCCAGTGA-3 0 (forward) and 5 0 -AAAGTTGCCCAAATTGCTGCT-3 0 (reverse); hFGF2, 5 0 -GGCTATGAAGGAAGATGGAAGATT-3 0 (forward) and 5 0 -TGCCACATACCAACTGGTGTATTT-3 0 (reverse); b-actin, 5 0 -CGACAGGATGCAGAAGGAGA-3 0 (forward) and 5 0 -TAGAAG-CATTTGCGGTGGAC-3 0 (reverse).
FGF2 assessment of medium supernatants
The cells were grown in 6-well plates and incubated with 0.1% FBS containing medium for 48 hours at 37 C in a 5% CO2 incubator. Supernatants were collected and centrifuged to remove cell debris. FGF2 levels in the supernatant were determined by following the eBioscience FlowCytomix detection kit instructions. For Western blot analysis, supernatants were further concentrated in the 10Â by Centricon Plus-70 centrifugal Filter Units-10 kDa (Millipore).
Statistical analysis
All data are representative of at least three separate experiments. Nonparametric one-way or two-way ANOVA was performed with SPSS version 12.0 software (SPSS), depending on the data. Comparisons between individual data points were analyzed by Student t test. Where P value was less than 0.05, the result was considered significant.
Results
Api5 expression in murine tumor cells is associated with immune resistance to antigen-specific CD8 þ T cells
To identify the master regulators governing the immuneresistance phenotype of A17 tumors, we analyzed a previous comparative microarray data of parental TC-1/P0 and TC-1/P3 (A17) cells (NCBI accession number GSE2774). Among several candidate genes, API5, an antiapoptotic factor expressed both in humans and mice, was found to be highly overexpressed in A17 cells as compared with their parental P0 cells both at the mRNA and protein levels (Supplementary Fig. S1 ; P < 0.05). Transfer of siRNA-targeting Api5 (siApi5) abolished protein expression of Api5 in A17 cells and led to a significant increase in active caspase-3 þ A17 cell populations exposed to E7-specific CD8 þ T cells (Fig. 1A) . Conversely, ectopic expression of Api5 in TC1/P0 parental cells rendered them resistant to CTL-mediated apoptosis (Fig. 1B) . Api5 was also overexpressed in murine cancer cells of skin and colorectal origin (B16 and CT26, respectively; Supplementary Fig. S2A ). Downregulation of Api5 led to enhanced CTL-mediated killing, whereas forced expression in Api5-negative targets (EL-4) led to immune resistance to antigen-specific lysis (Supplementary Fig. S2B and S2C).
To confirm the role of Api5 as an immune escape factor in vivo, C57BL/6 mice were inoculated subcutaneously with A17 cells and administered either siApi5-or siGFP-loaded chitosan nanoparticles (CNP) starting 7 days after initial tumor challenge followed by adoptive transfer of E7-specific CD8 þ T cells (Fig. 1C) . As expected, mice receiving E7-specific CTL demonstrated poor control of tumor growth; however, combination with siApi5 restored the immune sensitivity, resulting in significantly lower tumor volumes (P < 0.05). Conversely, forced expression of Api5 in parental TC-1/P0 cells led to immune resistance and unchecked tumor growth in the presence of antigen-specific CTL (Fig. 1D) . These results demonstrate that Api5 directly controls immune resistance in tumor cells both in vitro and in vivo.
posttranscriptional degradation. Furthermore, silencing Bim using siBim in TC-1/P0/no insert cells conferred resistance to CTL-mediated lysis (Fig. 2C ). Because phosphorylation of Bim by MAPKs has been shown to be critical in the degradation of Bim via proteasomal pathway (7), we next investigated whether Erk and other members of MAPKs were activated in TC-1/ P0/Api5 cells. Expression of the active form of Erk, Thr202/ Tyr204-pErk, was found to be highly elevated in TC-1/P0/Api5 cells compared with TC-1/P0/no insert cells (Fig. 2D ). Treatment with an Erk inhibitor, PD98059 (PD), reduced pErk and restored levels of Bim (Fig. 2E ), leading to enhanced killing of TC-1/P0/Api5 cells by E7-specific CTL (Fig. 2F) . Inhibition of p38, Akt, or PI3K activity using their specific inhibitors did not exert significant effect on apoptotic death of TC-1/P0/Api5 cells. To further confirm the roles of Erk in vivo, mice were challenged with TC-1/P0/Api5 cells and intratumorally injected with PD98059-loadedchitosan hydrogel along with E7-specific CTL. Delivery of PD98059 almost completely restored immune sensitivity of TC-1/P0/Api5 to E7-specific CTL (Fig. 2G) . Notably, PD98059 alone seemed to slightly reduce the tumor volume, but was not found to be statistically significant (P < 0.12). Taken together, these data corroborate the essential role of Erk in the degradation of Bim and the development of immune resistance in vivo.
API5 regulates immune resistance in human tumor cells
To explore the physiologic relevance of API5 in the development of immune resistance in patients with cancer, the expression of human API5 (hAPI5) was investigated in several human tumor cell lines arising from various tissue types ( Fig. 3A) . Among those tested, API5 was found to be markedly elevated in HeLa, PC-3, MCF-7, HCT116, and 526mel, while the expression of API5 in other tumor lines was comparable with that of nontumorigenic HEK293 cells (Fig. 3A) .When the expression of hAPI5 was silenced in HeLa, PC3, HCT116, and 526mel cells using siAPI5-loaded CNP ( linked to an HPV-16 E7 immunodominant CTL epitope (aa 49-57; HeLa/SCT-E7) for recognition by murineE7-specific CTL ( Fig. 3C; ref. 8) . The human melanoma cell line 526mel was chosen for high endogenous expression of the tumor-associated antigen, MART-1, and presentation of its HLA-A2-restricted epitope for recognition by MART-1-specific CTL (clone KKM; Supplementary Fig. S3 ). When HeLa/ SCT-E7 and 526mel cells were transfected with siAPI5, enhanced killing by E7-specific and MART-1-specific CTL was observed as compared with siGFP controls (Fig. 3C ). Similar enhancement was noted when the cellular activity of ERK was suppressed by treatment with PD98059 (Fig. 3D) . Thus, inhibition of ERK activity led to reduced BIM degradation and restored immune sensitivity to antigen-specific CTL in human.
To further demonstrate the role of hAPI5 in immune resistance, API5-negative HEK293D b cells and A375 melanoma cells were retrovirally transduced with hAPI5 and their immune sensitivity monitored. As expected, overexpression of API5 in both cell types caused elevation of pERK (>4 fold), and downregulation of BIM ($80% reduction) compared with no-insert controls (Fig. 3E) . Furthermore, expression of API5 in HEK293D b cells pulsed with E7-peptides or A375 melanoma cells pulsed with MART-1-peptides mounted resistance to apoptotic killing by their cognate antigen-specific CTL (Fig.  3F) , whereas inhibition of ERK by PD98059 restored immune sensitivity against API5 þ target cells (Fig. 3G) . The immune resistance by API5 overexpression was neither due to the defect in antigen processing through the MHC class I pathway and activation of T cells nor triggering of T-cell death (Supplementary Fig. S4 ). Taken together, our data indicate that API5 represents a shared immune escape factor in human cancer cells and endogenous overexpression of API5 confers immune resistance through an ERK-dependent mechanism while gene silencing of API5 restores immune sensitivity to antigen-specific CTL.
API5 activates ERK via the FGF2/FGFR1 pathway As a transcription factor, the ability of API5 to deliver an activation signal to ERK is not well defined. Because multiple receptor tyrosine kinases (RTK) can mediate ERK signaling in tumor cells, an antiphosphotyrosine receptor antibody array was performed to identify an upstream RTK, which might have been involved in API5-mediated ERK activation ( Supplementary Fig. S5A ). These arrays detected increased phosphorylation of FGFR1 and EGFR in HEK293/hAPI5 cells compared with HEK293/no insert cells. Because both API5 and FGF2 have been found to be upregulated in some malignancies (Supplementary Fig. S5B; ref. 9 ), we postulated that the FGF2/FGFR1 signaling pathway may be involved in delivering API5 signals downstream to ERK and initiating the subsequent antiapoptotic cascade by transcriptionally regulating FGF2 production. As expected, HEK293/hAPI5 cells expressed higher levels of phosphorylated FGFR1 (4.2-fold) and accompanying downstream signals (p-PKCd, p-ERK) compared with HEK293/no insert cells ( Fig. 4A; refs. 10, 11 ). We also found that both mRNA and protein levels of FGF2 were elevated among API5-overexpressing cells (Fig. 4B-D) . Knockdown or neutralization of secretable 18 kDa FGF2 by its specific siRNA (Fig. 4E) or mAbs (10 mg/mL of anti-FGF2; Fig. 4F ), respectively, led to a significant decrease in phosphorylated FGFR1 and downstream phosphorylation intermediates (p-PKCd, p-ERK) with concomitant elevation of cellular BIM, suggesting a direct role for FGF2 in the API5-induced antiapoptotic axis (9, 12) . Functionally, anti-FGF2mAb treatment of HKE293/hAPI5 cells led to increased sensitization to immune-mediated apoptosis when exposed to antigenspecific CTL (Fig. 4G) .
To further validate the significance of FGF2 in API5-mediated immune resistance, we assessed for a correlation in protein expression levels between FGF2 and API5 in various tumor cell lines (Fig. 4H) . A highly significant near 1:1 correlation was observed between API5 and FGF2 level, suggesting close relationship between these two proteins in all cell lines tested (Fig. 4H) . Consistent with these findings, we observed increased mRNA and protein levels of FGF2 among the A375 cells engineered to express hAPI5, and decreased levels of FGF2 when API5-expressing tumor cells (HeLa and 526mel) were treated with siAPI5 ( Fig. 4I-K) . Furthermore, antibody blockade of FGF2 led to a decrease in p-FGFR1, p-PKCd, and pERK, and reciprocal increase in BIM expression in API5-positive A375/hAPI5, HeLa, and 526mel cells (Fig. 4L) . These intracellular signaling events, occurring in the presence of neutralizing anti-FGF2 Abs, were accompanied by increased sensitization of API5 þ tumor targets to antigen-specific CTL-mediated lysis (Fig. 4L) . Taken together, these results provide strong evidence for FGF2 in mediating API5-induced immune resistance and degradation of BIM via the FGFR1/PKCd/ERK axis.
Silencing of PKCd leads to reconstitution of immune sensitivity in API5-expressing tumor cells
We next determined whether silencing of PKCd, a downstream molecule of FGFR1 signaling proximal to the ERK/ MAPK (13), was sufficient to inhibit API5-induced tumor immune resistance. Exposure of HeLa/SCT-E7 and526mel to rottlerin, an inhibitor of PKCd, resulted in a dose-dependent decrease in pERK levels and accompanying increase in BIM expression (Fig. 5A) . Furthermore, rottlerin treatment restored immune sensitivity of HeLa/SCT-E7 or 526mel cells to antigen-specific CTLs in vitro (Fig. 5B) . No effect of rottlerin was observed on API5 low HeLa/SCT-E7 or 526mel cells treated with siAPI5 (Fig. 5B) . To exclude potential offtarget effects of rottlerin, we performed the same experiment using siRNA targeting PKCd and observed similar results (left panels, Fig. 5C and D) . Consistent with this result, siPKCd-treated HeLa/SCT/E7 cells and 526mel cells were more susceptible to CTL-mediated killing (right panels, Fig. 5C and D) . Likewise, the in vivo tumor growth of 526mel-bearing NOD/SCID mice, in vivo siPKCd treatment using CNP before the adoptive transfer of MART-1-specific CD8 þ T cells (Fig. 5E ), demonstrated significantly lower tumor volume compared with those receiving control siGFP treatment (Fig. 5F ). Together, these data reveal that the activation of PKCd by FGF2/FGFR1 pathways in API5-overexpressing human tumor cells can lead to ERK activation and BIM degradation, hence controlling API5-mediated immune resistance both in vitro and in vivo.
Silencing of hAPI5 renders the tumor susceptible to immune-mediated control in a preclinical human melanoma model To demonstrate the potential translational relevance of API5-targeting and its downstream FGF2/FGFR1 signaling pathways in human tumor immunity, the efficacy of antigen-specific CTL recognizing MART-1 was tested in NOD/ SCID mice bearing established API5 þ human tumors. Mice receiving MART-1-specific CTL together with siAPI5, according to the schedule described in Fig. 6A , experienced significantly lower tumor burden at 49 days after tumor challenge compared with siAPI5 alone or CTL with control siRNA (Fig.  6B) . Tumors excised on day 49 were also substantially smaller by weight and size among mice receiving both MART-1-specific CTL and siAPI5 compared with either treatment alone (Fig. 6C) . Western blot analysis of ex vivo isolated tumors at day 49 after challenge demonstrated decreased FGF2, pFGFR1, pPKCd, and pERK and a concurrent increase in BIM proteins among those mice receiving siAPI5 treatment (Fig. 6D) , demonstrating that in vivo delivery of siAPI5 to the tumor and modulation of the tumor immune resistance pathway was successfully achieved. Treatment with siAPI5 resulted in an increased percentage of apoptotic tumor cells (Fig. 6F) , not as a result of increased CTL infiltration at the tumor site (Fig. 6E ), but rather due to enhanced lytic capacity of infiltrating CTL. Taken together, our data demonstrate that targeting and silencing of API5 or any of its downstream elements represents an attractive strategy for restoring immune sensitivity to resistant tumor cells.
Discussion
In this study, we identify API5 as a novel shared immune escape gene that plays a significant role in controlling immune resistance to antigen-specific T cells both in mouse and human cancer cells. Using murine TC-1/P3 (A17) lung cancer and human 526mel tumor cells that endogenously overexpressed API5, the role of API5 in controlling immune resistance was validated both in vitro and in vivo tumor models receiving their antigen-specific T-cell adoptive transfer. Specific knockdown of API5 in API5-positive tumor cells restored antigen-specific immune sensitivity, whereas the introduction of API5 into (Fig. 7 ).
API5 has previously been shown to be expressed in multiple cancers and contribute to tumor invasion and metastases (14, 15) ; however, its precise molecular mechanism of action remained unclear. Recent studies have shown that API5 caused suppression of apoptosis by inhibiting caspase-3-mediated DNA fragmentation (16) and in an E2F-dependent manner (17) . Depletion of API5 was shown to enhance the cytotoxic effect of chemotherapeutic drugs (18) , presumably by facilitating apoptosis of tumor cells in vivo. Notably, the proapoptotic factor, BIM, which can bind not only antiapoptotic BCL-2 family members, such as BCL-XL and BCL-2, but also BAK and BAX, was shown to be critical for paclitaxel-mediated cell death (19) . These observations, together with our findings presented here, suggest that BIM is likely a key mediator of cell death induced not only by chemotherapeutic agents, but also by antigen-specific T cells. Thus, controlling the cellular level of BIM by API5 seems to be an efficient means of conferring immune resistance in tumors.
The impact of API5 overexpression in tumor immune evasion has significant therapeutic implications. Although several clinical trials demonstrated tumor regression following antigen-specific vaccination or adoptive cellular therapy, a substantial proportion of patients experience partial responses and subsequent relapse (20, 21) . Altered expression of apoptosis-regulating molecules, such as BIM, represents one possible mechanism of immune resistance, which may be exacerbated by prior treatment with chemotherapy or irradiation (22) (23) (24) , both of which can induce upregulation of API5 and inhibition of apoptotic death pathways in tumor cells. The increasing availability of clinic-ready pharmacologic and biologic reagents that target and silence API5 or downstream elements including anti-FGF2, FGFR, ERK, and PKCd provides a rich opportunity for developing broadly applicable combinational strategies designed to control immune-resistant and recurrent human malignancies.
